XTX Topco Ltd Sells 37,836 Shares of Pfizer Inc. (NYSE:PFE)

XTX Topco Ltd lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 51.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,110 shares of the biopharmaceutical company's stock after selling 37,836 shares during the quarter. XTX Topco Ltd's holdings in Pfizer were worth $1,045,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. M&G Plc raised its stake in shares of Pfizer by 14.5% in the 2nd quarter. M&G Plc now owns 813,423 shares of the biopharmaceutical company's stock valued at $22,776,000 after purchasing an additional 103,254 shares in the last quarter. Maia Wealth LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at about $372,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of Pfizer by 1.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 1,648,811 shares of the biopharmaceutical company's stock valued at $46,134,000 after purchasing an additional 21,970 shares in the last quarter. Great Valley Advisor Group Inc. raised its stake in shares of Pfizer by 6.1% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 192,028 shares of the biopharmaceutical company's stock valued at $5,373,000 after purchasing an additional 10,993 shares in the last quarter. Finally, ORG Partners LLC raised its stake in shares of Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company's stock valued at $1,327,000 after purchasing an additional 44,458 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.52 during midday trading on Tuesday, reaching $25.58. The company had a trading volume of 43,228,141 shares, compared to its average volume of 38,528,086. The company's 50 day moving average price is $27.42 and its 200 day moving average price is $28.36. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $144.96 billion, a P/E ratio of 34.55, a P/E/G ratio of 0.70 and a beta of 0.65. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. During the same period in the prior year, the business posted ($0.17) earnings per share. The company's revenue was up 31.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.57%. Pfizer's dividend payout ratio is presently 227.03%.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. The trade was a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

PFE has been the subject of a number of recent research reports. Bank of America reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday. Citigroup began coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a "neutral" rating and a $30.00 price target for the company. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price target for the company. StockNews.com downgraded shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a "market perform" rating and a $32.00 price objective on the stock. One research analyst has rated the stock with a sell rating, nine have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $32.64.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.